- PR Newswire•18 days ago
BASEL, Switzerland, Feb. 3, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that it has entered into a $55.0 million debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), a leader in customized debt financing for companies in life sciences and technology-related markets. "This financing provides Axovant additional flexibility to pursue its mission of developing comprehensive solutions for patients with dementia," stated Vivek Ramaswamy, Chief Executive Officer of Axovant Sciences.
- Business Wire•19 days agoHercules Announces Date for Release of Fourth Quarter and Full-Year 2016 Financial Results and Conference Call
Hercules Capital, Inc. , the leading specialty finance company to innovative, venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today announced that it has scheduled its fourth quarter and full-year 2016 financial results conference call for Thursday, February 23, 2017, at 2:00 p.m.
- Business Wire•20 days ago
Hercules Capital, Inc. , the leading specialty finance company to innovative, venture growth, pre-IPO and M&A stage companies backed by leading venture capital firms, today announced that Manuel A.
HTGC : Summary for Hercules Capital, Inc. Common S - Yahoo Finance
Hercules Capital, Inc. (HTGC)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||15.18 - 15.33|
|52 Week Range||9.95 - 15.33|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.36|
|Dividend & Yield||1.24 (8.17%)|
|1y Target Est||N/A|